Page 44 - Read Online

Page 66 Olivera et al. Cancer Drug Resist 2019;2:53-68 I http://dx.doi.org/10.20517/cdr.2018.25

results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC). Genet Med 2017;19:215-23.
6. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-Van Der Zee AH, et al. Pharmacogenetics: from Bench to Byte - an update of
guidelines. Clin Pharmacol Ther 2011;89:662-73.
7. García-González X, Cabaleiro T, Herrero MJ, McLeod H, López-Fernández LA. Clinical implementation of pharmacogenetics. Drug
Metab Pers Ther 2016;31:9-16.
8. U S Food and Drug Administration. Available from: https://www.fda.gov/. [Last accessed on 18 Feb 2019]
9. European Medicines Agency. Available from: https://www.ema.europa.eu/en. [Last accessed on 18 Feb 2019]
10. Pharmaceuticals and Medical Devices Agency. Available from: http://www.pmda.go.jp/english/. [Last accessed on 18 Feb 2019]
11. Drugs and Health Products - Canada.ca. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products.html.
[Last accessed on 18 Feb 2019]
12. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.
Clin Pharmacol Ther 2011;89:464-7.
13. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, et al. Pharmacogenetics: from Bench to Byte. Clin Pharmacol Ther
2008;83:781-7.
14. Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, et al. A comparison of the guidelines of the Clinical Pharmacogenetics
Implementation Consortium and the Dutch Pharmacogenetics Working Groups. Clin Pharmacol Ther 2018;103:599-618.
15. Lee JW, Pussegoda K, Rassekh SR, Liu G, Hwang S, et al. Clinical practice recommendations for the management and prevention of
cisplatin-induced hearing loss using Pharmacogenetic markers. Ther Drug Monit 2016;38:423-31.
16. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven Leeder J. Prediction of CYP2D6 phenotype from genotype across world
populations. Genet Med 2017;19:69-76.
17. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. Clinical Pharmacogenetics Implementation Consortium
guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-91.
18. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. Clinical pharmacogentics implementation consortium guidelines
for thiopurine methyltransferase genotype and thiopurine dosing: 2013 Update. Clin Pharmacol Ther 2013;93:324-5.
19. Relling MV, Schaw M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC)
guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 2018; doi: 10.1002/
cpt.1304.
20. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther
2018;103:210-6.
21. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC)
guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 2017;102:213-8.
22. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC)
guideline for CYP2D6 and Tamoxifen therapy. Clin Phramacol Ther 2018;103:770-7.
23. Alsous M, Yousef AM, Abdel Jalil M, Zawiah M, Yacoub S, et al. Genetic Polymorphism of Thiopurine S-methyltransferase in Children
with Acute Lymphoblastic Leukemia in Jordan. Asian Pac J Cancer Prev 2018;19:199-205.
24. Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World
J Gastroenterol 2011;17:4166-73.
25. Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, et al. NUDT15 polymorphisms alter thiopurine metabolism and
hematopoietic toxicity. Nat Genet 2016;48:367-73.
26. Yang SK, Hong M, Baek J, Choi H, Zhao W, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced
leukopenia. Nat Genet 2014;46:1017-20.
27. Chiengthong K, Ittiwut C, Muensri S, Sophonphan J, Sosothikul D, et al. NUDT15 c.415C>T increases risk of 6-mercaptopurine
induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica 2016;101:e24-6.
28. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/
HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of
individual patient data. Lancet Oncol 2015;16:1639-50.
29. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50.
30. Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based
chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One 2013;8:e58489.
31. Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, et al. Intestinal microflora and digestive toxicity of irinotecan in mice.
Clin Cancer Res 2006;12:1299-307.
32. Lévesque E, Bélanger AS, Harvey M, Couture F, Jonker D, et al. Refining the UGT1A haplotype associated with irinotecan-induced
hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp
Ther 2013;345:95-101.
33. Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC)
Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther 2016;99:363-9.
34. Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, et al. UGT1A1 genotype and irinotecan therapy: general review and
implementation in routine practice. Fundam Clin Pharmacol 2015;29:219-37.
35. Kovac AL. Comparative Pharmacology and guide to the use of the serotonin 5-HT3 receptor antagonists for postoperative nausea and